SCHEMBL3404495

SCHEMBL3404495

COC(C)OP(O)(O)=S

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL784167 0.73
SCHEMBL1514201 0.72
SCHEMBL2524893 0.72 CA2 (0.33)
SCHEMBL28132111 0.69
SCHEMBL3501702 0.69
SCHEMBL7731451 0.69
Phosphoric Acid SCHEMBL26662213 0.67 CA2 (0.38)
Phosphoramidic Acid SCHEMBL220946 0.67 LAP3 (0.32)
SCHEMBL20335184 0.65
SCHEMBL2048661 0.65 CTSA (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10760076-B2 Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansion PROQR THERAPEUTICS II B.V. (NL) 2020-09-01 US claimed
US-20240229026-A1 CHIRAL CONTROL WAVE LIFE SCIENCES LTD. (SG) 2024-07-11 US disclosed
WO-2024009306-A1 COMPOSITIONS AND METHODS FOR TREATING PRIMARY CILIARY DYSKINESIA SKIP THERAPEUTICS LTD. (IL) 2024-01-11 WO disclosed
WO-2023200893-A1 SMALL MOLECULE ENHANCERS OF ANTISENSE OLIGO ACTIVITY OREGON STATE UNIVERSITY (US) 2023-10-19 WO disclosed
EP-4219516-A2 CHIRAL CONTROL Wave Life Sciences Ltd. (SG) 2023-08-02 EP disclosed
US-11643657-B2 Chiral control WAVE LIFE SCIENCES LTD. (SG) 2023-05-09 US disclosed
EP-2872147-B1 METHOD FOR MAKING CHIRAL OLIGONUCLEOTIDES WAVE LIFE SCIENCES LTD (SG) 2022-12-21 EP disclosed
US-20220280548-A1 COMBINATION THERAPY FOR SPINAL MUSCULAR ATROPHY BIOGEN MA INC. (US) 2022-09-08 US disclosed
EP-4013387-A1 COMBINATION THERAPY FOR SPINAL MUSCULAR ATROPHY Biogen MA Inc. (US) 2022-06-22 EP disclosed
US-20210308281-A1 COMBINATION THERAPY FOR SPINAL MUSCULAR ATROPHY BIOGEN MA INC. (US) 2021-10-07 US disclosed
EP-2454370-A1 MICRORNA-24 Julius-Maximilians-Universität Würzburg (DE) 2012-05-23 EP disclosed
WO-2011006669-A1 MICRORNA-24 JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) 2011-01-20 WO disclosed
EP-2249874-A1 METHODS AND MEANS FOR TREATING DNA REPEAT INSTABILITY ASSOCIATED GENETIC DISORDERS ProSensa Holding BV (NL) 2010-11-17 EP disclosed
WO-2009099326-A1 METHODS AND MEANS FOR TREATING DNA REPEAT INSTABILITY ASSOCIATED GENETIC DISORDERS PROSENSA HOLDING BV (NL) 2009-08-13 WO disclosed
EP-2049664-A1 METHODS AND MEANS FOR TREATING DNA REPEAT INSTABILITY ASSOCIATED GENETIC DISORDERS Prosensa Technologies B.V. (NL) 2009-04-22 EP disclosed
WO-2008018795-A1 METHODS AND MEANS FOR TREATING DNA REPEAT INSTABILITY ASSOCIATED GENETIC DISORDERS PROSENSA TECHNOLOGIES B.V. (NL) 2008-02-14 WO disclosed
EP-1874791-A1 METHODS AND COMPOSITIONS FOR REGULATED EXPRESSION OF NUCLEIC ACID AT POST-TRANSCRIPTIONAL LEVEL The University of North Carolina at Chapel Hill (US) 2008-01-09 EP disclosed
WO-2006119137-A1 METHODS AND COMPOSITIONS FOR REGULATED EXPRESSION OF NUCLEIC ACID AT POST-TRANSCRIPTIONAL LEVEL THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2006-11-09 WO disclosed
EP-1529105-A1 METHODS TO REPROGRAM SPLICE SITE SELECTION IN PRE-MESSENGER RNAS Université de Sherbrooke (CA) 2005-05-11 EP disclosed
WO-2004015106-A1 METHODS TO REPROGRAM SPLICE SITE SELECTION IN PRE-MESSENGER RNAS UNIVERSITé DE SHERBROOKE (CA) 2004-02-19 WO disclosed